How to treat adverse reactions caused by evantumumab?

Introduction: Amivantamab is a prescription drug mainly used in combination with carboplatin and pemetrexed for the first-line treatment of non-small cell lung cancer (NSCLC). On March 1, 2024, the U.S. Food and Drug Administration approved evantumumab in combination with carboplatin and pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 20 insertion mutations detected by an FDA-approved test.

Adverse reactions of evantumumab

The most common adverse reactions include rash, nausea, vomiting, fatigue, edema, stomatitis, cough, constipation, infusion-related reactions, paronychia, muscle pain, dyspnea, etc. The most common grade 3 or 4 laboratory abnormalities include lymphopenia, albumin decrease, potassium decrease, alkaline phosphatase increase, glucose increase, gamma-glutamyl transferase increase, etc.

Therapeutic measures of evantumumab

1. Infusion reaction: If an infusion reaction occurs, the infusion should be interrupted immediately. Depending on the severity of the reaction, the infusion rate may need to be reduced or the use of evantumumab may need to be permanently discontinued.

2. Skin rash: You may need to use antihistamines or topical corticosteroids as directed by your doctor to relieve symptoms.

3. Muscle pain: Nonsteroidal anti-inflammatory drugs or other analgesics can be used to relieve pain.

4. Dyspnea: Immediate medical intervention may be required, including oxygen therapy and bronchodilators.

5. Nausea and vomiting: Anti-nausea medications can be used to control these symptoms.

6. Fatigue: May need to be managed through rest, nutritional support, and appropriate physical activity.

7. Edema: It may be necessary to use diuretics or adjust the salt intake in the diet to control it.

8. Constipation: It can be relieved by increasing dietary fiber intake, using laxatives or adjusting diet.

9. Cough: You may need to use cough suppressants or bronchodilators.

Patients should closely monitor their physical condition when using evantumumab and report any symptoms of discomfort to their doctors in a timely manner so that doctors can adjust the treatment plan or take corresponding treatment measures according to the specific situation.